About US
Contact us
-
FDA panel unanimously backs Valeant's suicide-linked psoriasis med, but serious competition awaitsMembers of an FDA-assembled panel of experts definitely agreed on one thing Tuesday: The benefits of Valeant Pharmaceuticals'psoriasis treatmentbrodalumaboutweigh its risks. But how to manage those ri2016/8/4
-
UK High Court judicial review rules NHS to fund for HIV prevention drugThe UK High Court judicial review has ruled that National Health Service (NHS) England will be responsible for the commissioning of Pre-Exposure Prophylaxis (PrEP) drug, a measure used to prevent HIV2016/8/3
-
AstraZeneca and Chi-Med amend agreement for savolitinib to treat several cancersUK-based pharmaceutical company AstraZeneca and Chinese healthcare group Chi-Med have amended the 2011 worldwide licensing, co-development, and commercialisation agreement for savolitinib to treat a n2016/8/3
-
The Art and Science of Forecasting with Clinical InformaticsThe art and science of forecasting with clinical informatics The pharmaceutical industry continues to strive to improve the quality and efficiency of clinical trials but many challenges remain with2016/8/2
-
Otsuka's Abilify leads Medicaid spending, report finds, with Gilead's hep C meds close behindAmid a period of intense drug pricing scrutiny, data are out on the costliest drugs to Medicaid, with some of pharma's biggest names among the highest-ranking brands. It's a tale of the Medicaid popul2016/8/2
-
Lymphoma trial failure endangers Roche's Gazyva growth plans as Rituxan biosims loomRoche’s Gazyva fell short in a late-stage lymphoma trial, jeopardizing the company’s expansion plans for the Rituxan follow-up. The newer med failed to best gold-standard Rituxan in previously untreat2016/8/1
-
Revlimid snags MCL nod in Europe to take on J&J's ImbruvicaCelgene blood cancer giant Revlimid has picked up another European approval. But as the company gears up to launch the med in its new indication, it’s already got a familiar foe waiting to receive it.2016/8/1
-
GSK and Janssen sign licence agreement for CNTO 7160 asthma treatment worldwideBritish pharmaceutical company GlaxoSmithKline (GSK) has entered into an exclusive, worldwide licence agreement with Janssen Sciences Ireland for CNTO 7160 to treat patients with severe asthma. CNTO2016/7/29
-
IBM team develops new lab-on-a-chip technology for physicians to detect cancerScientists from IBM Research have developed a new lab-on-a-chip technology that can be used to separate biological particles at the nanoscale, thereby allowing physicians to detect diseases such as ca2016/7/29
-
Shire’s SHP626 gets FDA Fast Track designation for NASH with liver fibrosisIrish biopharmaceutical company Shire has been granted the US Food and Drug Administration (FDA) Fast Track designation for SHP626 (volixibat) to treat non-alcoholic steatohepatitis (NASH) with liver2016/7/28